Clinical Trial Datasets
ACTG 364 clinical trial
Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team., Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001 Aug 9;345(6):398-407.
Bosch RJ, Downey GF, Katzenstein DA, Hellmann N, Bacheler L, Albrecht MA; ACTG 364 Study Team, Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz. AIDS. 2003 Nov 7;17(16):2395-6.
Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA; ACTG 364 Study Team, Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS. 2003 Apr 11;17(6):821-30.
Nucleotide sequences in fasta format
Composite alignment (of sequences at baseline)
List of sequences with stop codon, ambiguity codon and unusual residues
Method: Direct PCR, Dideoxy terminator sequencing
Integrated view of ARV, genotypes, RNA and CD4 on 159 patients
The Microsoft Access database ACTG364Summary.mdb was created on 159 patients for whom sequences are available and contains tables with treatment, mutations, RNA levels and CD4 counts.
The files contained ACTG364Summary.mdb (the description of each file)